Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies

Despite 20 years of research, a vaccine to prevent hepatitis C virus (HCV) infection has not been developed. A vaccine to prevent HCV will need to induce broadly reactive immunity able to prevent infection by the 7 genetically and antigenically distinct genotypes circulating world-wide. HCV encodes two surface exposed glycoproteins, E1 and E2 that function as a heterodimer to mediate viral entry. Neutralizing antibodies (NAbs) to both E1 and E2 have been described with the major NAb target being E2. The function of E2 is to attach virions to host cells via cell surface receptors that include, but is not limited to, the tetraspanin CD81 and scavenger receptor class B type 1. However, E2 has developed a number of immune evasion strategies to limit the effectiveness of the NAb response and possibly limit the ability of the immune system to generate potent NAbs in natural infection. Hypervariable regions that shield the underlying core domain, subdominant neutralization epitopes and glycan shielding combine to make E2 a difficult target for the immune system. This review summarizes recent information on the role of NAbs to prevent HCV infection, the targets of the NAb response and structural information on glycoprotein E2 in complex with neutralizing antibodies. This new information should provide a framework for the rational design of new vaccine candidates that elicit highly potent broadly reactive NAbs to prevent HCV infection.

[1]  Matthew J. Brauer,et al.  Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. , 1991, Virology.

[2]  N. Kato,et al.  Characterization of hypervariable regions in the putative envelope protein of hepatitis C virus. , 1992, Biochemical and biophysical research communications.

[3]  N. Kato,et al.  Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus , 1993, Journal of virology.

[4]  N. Kato,et al.  Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70 , 1994, Japanese journal of cancer research : Gann.

[5]  A. Weiner,et al.  Vaccination of chimpanzees against infection by the hepatitis C virus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  E. Schreier,et al.  Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. , 1995, Virology.

[7]  M. Shapiro,et al.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Zibert,et al.  Early antibody response against hypervariable region 1 is associated with acute self‐limiting infections of hepatitis C virus , 1997, Hepatology.

[9]  M. Houghton,et al.  Binding of hepatitis C virus to CD81. , 1998, Science.

[10]  A. Nicosia,et al.  Identification of Amino Acid Residues in CD 81 Critical for Interaction with Hepatitis C Virus Envelope Glycoprotein E 2 , 1999 .

[11]  J. Allain,et al.  Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the hepatitis C virus in rabbits. , 1999, Virology.

[12]  A. Widell,et al.  Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. , 2000, The Journal of general virology.

[13]  S. Levy,et al.  Human Monoclonal Antibodies That Inhibit Binding of Hepatitis C Virus E2 Protein to CD81 and Recognize Conserved Conformational Epitopes , 2000, Journal of Virology.

[14]  A. Nicosia,et al.  Identification of Amino Acid Residues in CD81 Critical for Interaction with Hepatitis C Virus Envelope Glycoprotein E2 , 2000, Journal of Virology.

[15]  A Cerino,et al.  Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? , 2001, Antiviral research.

[16]  J. Allain,et al.  Production and Characterization of Monoclonal Antibodies Specific for a Conserved Epitope within Hepatitis C Virus Hypervariable Region 1 , 2001, Journal of Virology.

[17]  G. Deléage,et al.  Conservation of the Conformation and Positive Charges of Hepatitis C Virus E2 Envelope Glycoprotein Hypervariable Region 1 Points to a Role in Cell Attachment , 2001, Journal of Virology.

[18]  R. Clayton,et al.  Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. , 2001, The Journal of general virology.

[19]  H. Drummer,et al.  Identification of the Hepatitis C Virus E2 Glycoprotein Binding Site on the Large Extracellular Loop of CD81 , 2002, Journal of Virology.

[20]  R. Cortese,et al.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus , 2002, The EMBO journal.

[21]  B. Bartosch,et al.  Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes , 2003, The Journal of experimental medicine.

[22]  A. Maerz,et al.  Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins , 2003, FEBS letters.

[23]  C. Cheng‐Mayer,et al.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Tramontano,et al.  Binding of the Hepatitis C Virus E2 Glycoprotein to CD81 Is Strain Specific and Is Modulated by a Complex Interplay between Hypervariable Regions 1 and 2 , 2003, Journal of Virology.

[25]  C. Rice,et al.  CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection , 2004, Journal of Virology.

[26]  T. Liang,et al.  Human Monoclonal Antibody to Hepatitis C Virus E1 Glycoprotein That Blocks Virus Attachment and Viral Infectivity , 2004, Journal of Virology.

[27]  H. Drummer,et al.  Hepatitis C Virus Glycoprotein E2 Contains a Membrane-proximal Heptad Repeat Sequence That Is Essential for E1E2 Glycoprotein Heterodimerization and Viral Entry* , 2004, Journal of Biological Chemistry.

[28]  J. Dubuisson,et al.  Hepatitis C Virus E2 Has Three Immunogenic Domains Containing Conformational Epitopes with Distinct Properties and Biological Functions , 2004, Journal of Virology.

[29]  P. Lambert,et al.  Can successful vaccines teach us how to induce efficient protective immune responses? , 2005, Nature Medicine.

[30]  M. Houghton,et al.  Prospects for a vaccine against the hepatitis C virus , 2005, Nature.

[31]  J. Pawlotsky,et al.  Human Serum Facilitates Hepatitis C Virus Infection, and Neutralizing Responses Inversely Correlate with Viral Replication Kinetics at the Acute Phase of Hepatitis C Virus Infection , 2005, Journal of Virology.

[32]  R. Bartenschlager,et al.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome , 2005, Nature Medicine.

[33]  Toshiaki Maruyama,et al.  Complete Replication of Hepatitis C Virus in Cell Culture , 2005, Science.

[34]  D. Lavillette,et al.  Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein , 2005, Journal of Virology.

[35]  A. Tarr,et al.  Monoclonal Antibody AP 33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E 2 Envelope Glycoprotein , 2005 .

[36]  S. Lemon,et al.  Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Tarr,et al.  Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding , 2006, Journal of Virology.

[38]  F. Alvarez,et al.  Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. , 2006, Virology.

[39]  A Conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr Motif in Hepatitis C Virus Glycoprotein E2 Is a Determinant of CD81 Binding and Viral Entry , 2006, Journal of Virology.

[40]  D. Jackson,et al.  Exploiting Information Inherent in Binding Sites of Virus-Specific Antibodies: Design of An HCV Vaccine Candidate Cross-Reactive with Multiple Genotypes , 2006, Antiviral therapy.

[41]  R. Bartenschlager,et al.  Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33 , 2006, Hepatology.

[42]  H. Drummer,et al.  Expression and Characterization of a Minimal Hepatitis C Virus Glycoprotein E2 Core Domain That Retains CD81 Binding , 2007, Journal of Virology.

[43]  A. Tarr,et al.  Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein , 2007, Journal of Virology.

[44]  A. Tarr,et al.  Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. , 2007, The Journal of general virology.

[45]  C. Rice,et al.  Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. , 2007, Gastroenterology.

[46]  F. Penin,et al.  The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein , 2007, Journal of Virology.

[47]  H. Drummer,et al.  Expression and Characterization of a Minimal Hepatitis C Virus Glycoprotein E 2 Core Domain That Retains CD 81 Binding , 2007 .

[48]  S. Emerson,et al.  Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus , 2007, Journal of Virology.

[49]  P. Schürmann,et al.  Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C , 2007, Proceedings of the National Academy of Sciences.

[50]  A. Tarr,et al.  Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus , 2007, Proceedings of the National Academy of Sciences.

[51]  Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein , 2008, The Journal of general virology.

[52]  A. Moya,et al.  Using evolutionary tools to refine the new hypervariable region 3 within the envelope 2 protein of hepatitis C virus. , 2008, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[53]  R. Purcell,et al.  Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver–chimeric mice from infection with a homologous hepatitis C virus strain , 2008, Hepatology.

[54]  G. Leroux-Roels,et al.  Anti‐CD81 antibodies can prevent a hepatitis C virus infection in vivo , 2008, Hepatology.

[55]  D. Burton,et al.  Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge , 2008, Nature Medicine.

[56]  G. Szabo,et al.  Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E 2 Envelope Glycoprotein of Hepatitis C Virus , 2009 .

[57]  S. Ray,et al.  Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. , 2009, Gastroenterology.

[58]  G. Szabo,et al.  Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C Virus , 2009, Journal of Virology.

[59]  M. Major,et al.  Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity , 2009, Proceedings of the National Academy of Sciences.

[60]  J. Ball,et al.  Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes , 2009, PloS one.

[61]  S. Ray,et al.  Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. , 2010, Gastroenterology.

[62]  S. Ciesek,et al.  Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes , 2010, Journal of Virology.

[63]  Stuart C. Ray,et al.  Acceleration of Hepatitis C Virus Envelope Evolution in Humans Is Consistent with Progressive Humoral Immune Selection during the Transition from Acute to Chronic Infection , 2010, Journal of Virology.

[64]  P. Roingeard,et al.  Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions , 2010, Journal of Virology.

[65]  K. Meyer,et al.  Characterization of antibodies induced by vaccination with Hepatitis C virus envelope glycoproteins , 2010, The Journal of infectious diseases.

[66]  F. Cosset,et al.  Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation , 2011, Expert Reviews in Molecular Medicine.

[67]  M. Krieger,et al.  Identification of the PDZ3 Domain of the Adaptor Protein PDZK1 as a Second, Physiologically Functional Binding Site for the C Terminus of the High Density Lipoprotein Receptor Scavenger Receptor Class B Type I* , 2011, The Journal of Biological Chemistry.

[68]  M. Merchlinsky,et al.  New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles. , 2011, Vaccine.

[69]  Stanley M. Lemon,et al.  Neutralizing Monoclonal Antibodies against Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a Postattachment Step , 2011, Journal of Virology.

[70]  H. Drummer,et al.  The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity. , 2011, The Journal of general virology.

[71]  G. Nabel Rational design of vaccines for AIDS and influenza. , 2012, Transactions of the American Clinical and Climatological Association.

[72]  J. Bukh,et al.  Human Monoclonal Antibodies to a Novel Cluster of Conformational Epitopes on HCV E2 with Resistance to Neutralization Escape in a Genotype 2a Isolate , 2012, PLoS pathogens.

[73]  J. Bukh,et al.  Cooperativity in Virus Neutralization by Human Monoclonal Antibodies to Two Adjacent Regions Located at the Amino Terminus of Hepatitis C Virus E2 Glycoprotein , 2012, Journal of Virology.

[74]  I. Wilson,et al.  Structure of Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Site 412 to 423 in Complex with Antibody AP33 , 2012, Journal of Virology.

[75]  Heiyoung Park,et al.  Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. , 2012, The Journal of infectious diseases.

[76]  A. Tarr,et al.  The role of neutralizing antibodies in hepatitis C virus infection. , 2012, The Journal of general virology.

[77]  R. Purcell,et al.  Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees , 2012, PLoS pathogens.

[78]  F. Penin,et al.  Disulfide Bonds in Hepatitis C Virus Glycoprotein E1 Control the Assembly and Entry Functions of E2 Glycoprotein , 2012, Journal of Virology.

[79]  D. Lavillette,et al.  Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2. , 2012, The Biochemical journal.

[80]  D. Burton,et al.  Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1 , 2012, Proceedings of the National Academy of Sciences.

[81]  K. Ishii,et al.  Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice. , 2013, Gastroenterology.

[82]  Robyn L. Stanfield,et al.  Hepatitis C Virus E2 Envelope Glycoprotein Core Structure , 2013, Science.

[83]  F. Penin,et al.  Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization. , 2013, The Journal of infectious diseases.

[84]  Christopher T. Jones,et al.  A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans , 2013, PloS one.

[85]  A. Meola,et al.  Structural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization Escape , 2013, PLoS pathogens.

[86]  J. Marcotrigiano,et al.  Structure of the Core Ectodomain of the Hepatitis C Virus Envelope Glycoprotein 2 , 2014, Nature.

[87]  Hepatitis C Virus , 2016, Annals of Internal Medicine.